SPR-based fragment screening: advantages and applications.
about
Process of Fragment-Based Lead Discovery-A Perspective from NMRFragment screening and HIV therapeuticsThe Role of Medical Structural Genomics in Discovering New Drugs for Infectious DiseasesDiscovery of Leukotriene A4 Hydrolase Inhibitors Using Metabolomics Biased Fragment Crystallography †Fragment-based lead discovery: screening and optimizing fragments for thermolysin inhibitionFragment-based screening by X-ray crystallography, MS and isothermal titration calorimetry to identify PNMT (phenylethanolamine N-methyltransferase) inhibitorsHitting the target: fragment screening with acoustic in situ co-crystallization of proteins plus fragment libraries on pin-mounted data-collection micromeshes.Surface plasmon resonance: a versatile technique for biosensor applicationsCreating novel activated factor XI inhibitors through fragment based lead generation and structure aided drug designIdentification of Small Molecule Inhibitors of Tau Aggregation by Targeting Monomeric Tau As a Potential Therapeutic Approach for TauopathiesDevelopment of phase detection schemes based on surface plasmon resonance using interferometryBuffer optimization of thermal melt assays of Plasmodium proteins for detection of small-molecule ligandsHTS and hit finding in academia--from chemical genomics to drug discovery.The antituberculosis antibiotic capreomycin inhibits protein synthesis by disrupting interaction between ribosomal proteins L12 and L10.Fragment screening of infectious disease targets in a structural genomics environmentTargeting protein-protein interactions for therapeutic intervention: a challenge for the future.Emerging role of surface plasmon resonance in fragment-based drug discovery.Computational fragment-based screening using RosettaLigand: the SAMPL3 challenge.In situ drug-receptor binding kinetics in single cells: a quantitative label-free study of anti-tumor drug resistanceAffinity-based screening techniques: their impact and benefit to increase the number of high quality leads.Advances in fragment-based drug discovery platforms.Evolutions in fragment-based drug design: the deconstruction-reconstruction approachA surface plasmon resonance approach to monitor toxin interactions with an isolated voltage-gated sodium channel paddle motif.Halogen-enriched fragment libraries as chemical probes for harnessing halogen bonding in fragment-based lead discovery.Fragment screening by surface plasmon resonance.Repositioning the substrate activity screening (SAS) approach as a fragment-based method for identification of weak binders.State-of-the-art strategies for targeting protein-protein interactions by small-molecule inhibitors.One Question, Multiple Answers: Biochemical and Biophysical Screening Methods Retrieve Deviating Fragment Hit Lists.Relationship between hot spot residues and ligand binding hot spots in protein-protein interfaces.Adenylating enzymes in Mycobacterium tuberculosis as drug targets.Progress in the discovery of small-molecule inhibitors of bromodomain--histone interactions.Fragment informatics and computational fragment-based drug design: an overview and update.Surface plasmon resonance (SPR) biosensors in pharmaceutical analysis.Use of Microarrays as a High-Throughput Platform for Label-Free Biosensing.Spatially addressable chemoselective C-terminal ligation of an intein fusion protein from a complex mixture to a hydrazine-terminated surface.Developments in SPR Fragment Screening.Identification of an anti-TB compound targeting the tyrosyl-tRNA synthetase.Compound Design by Fragment-Linking.Development of a steady-state FRET-based assay to identify inhibitors of the Keap1-Nrf2 protein-protein interaction.Protein-Templated Formation of an Inhibitor of the Blood Coagulation Factor Xa through a Background-Free Amidation Reaction.
P2860
Q26738768-E503C85B-EF9F-4C3B-853A-9CA61C503086Q26826945-752048D4-4D2D-449E-844F-26B6681CAE5BQ27489856-1A0BB47D-6583-47DA-A177-1D2516917A58Q27646546-DB1CD534-999D-4761-844D-73B4ADE40CA9Q27660547-9417B290-6BA1-4BE9-BACD-69F3712AEE15Q27663569-20F0E07A-6FD4-45DE-938E-A4CE632F4EBBQ27683710-F91D800C-7F67-4F15-809B-6F8393757410Q28084507-48BE4EF6-295E-4E2C-AC90-84C7DCEBCAD4Q28543133-65108E45-6245-4111-BF6C-DEE63B200E3BQ28597211-2263E7A9-6DC1-4A4A-8566-C32E61623518Q30427848-DCBA5C88-6DC6-4C62-9CC0-E473BC44EBDAQ33453099-77560BF0-6FD9-4311-B473-7B175FC7D62FQ33621193-658C5A02-1F34-4E2F-A941-E45B78B71D47Q33622886-5C969F39-3B35-41FA-B4AA-B4CF1EB2B785Q33836468-D994CEBB-C7E7-4C7C-9AFD-C7DDE9AFB599Q33852396-DDC111CB-7874-4C15-B0B5-A2BB0BC552E9Q34049517-2192E1B7-332A-4611-ADA2-5B0B83AA9264Q34127928-5613FF65-F4ED-4B48-AE63-9CD15F7E4209Q34334146-2C70C0EC-A5C0-4972-A669-410C049304E2Q34349935-0C414A39-A7AE-4D45-9AAB-9DBD10531102Q34616682-7757D961-3D70-4DDB-8AEA-D526AD88AC0DQ35009555-39A7205A-6001-4881-8383-1BBDA940C161Q35014380-A90868C8-FB68-4CD2-B5C2-E92C4518AA4BQ35181268-D990E31C-B2D3-411F-A732-C030FD43ED4AQ35181877-DBBDFE40-1320-4120-8667-7404D210721DQ35231270-2F7C6B3F-909C-4A31-B70B-6C70F2ECE599Q35738960-248B2EDE-F456-4B3E-B9C8-5E54B521EB5BQ35741775-E80FE5F3-7AAA-4DFA-98DD-F203092B39B2Q36758601-15401377-9212-4521-9F86-C8F832DA7570Q37257062-63D13F41-C41C-437D-B000-C394BF751D9AQ37940197-5A317C9B-89B9-4FA8-818A-A419C22C16C5Q37995087-07CDEFBA-059A-428A-B467-FCB446C7537CQ38307244-88C11D6A-812E-46AE-A295-5D84964E4C9AQ38392123-545ADC87-FB7E-455D-9236-AB87FF68867BQ38662300-7ABC64B5-14FB-40A2-9783-65FA1B2B9105Q38762947-D5C77305-FDFA-41CB-B413-B18E9D3FDE47Q38877288-D1AE52A4-E9D2-403F-A182-AC4671E3773BQ38910944-56509F46-8339-4B61-A7EB-9A259955DD5DQ41897701-836509FC-37D5-4F84-9EC7-FD4F6B6270E2Q42314613-97427484-7DC2-494C-9AAD-12FFA0A5CCC8
P2860
SPR-based fragment screening: advantages and applications.
description
2007 nî lūn-bûn
@nan
2007 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
SPR-based fragment screening: advantages and applications.
@ast
SPR-based fragment screening: advantages and applications.
@en
SPR-based fragment screening: advantages and applications.
@nl
type
label
SPR-based fragment screening: advantages and applications.
@ast
SPR-based fragment screening: advantages and applications.
@en
SPR-based fragment screening: advantages and applications.
@nl
prefLabel
SPR-based fragment screening: advantages and applications.
@ast
SPR-based fragment screening: advantages and applications.
@en
SPR-based fragment screening: advantages and applications.
@nl
P2093
P1476
SPR-based fragment screening: advantages and applications.
@en
P2093
P304
P356
10.2174/156802607782341073
P577
2007-01-01T00:00:00Z